In June, Morphosys AG acquired Constellation Pharmaceuticals Inc. in a deal worth $1.7 billion in which the German biotech monetizes a royalty from a big-selling antibody, spending the lump sum on research into small-molecule BET inhibitors. It’s a bold move and one that perhaps demonstrates a renewed interest in small-molecule drugs after a period when antibody-based molecules have been the dominant force in the market for branded drugs.
29 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its interim results for the six months ended 31 January 2021.
20 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect.
Clive Dix talks Proactive London's Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln.
The group will receive €7mln upfront, plus €11mln in pre-clinical payments.
The deal is for their oral IL-17A inhibitor programme, currently IL-17 monoclonal antibodies are administered by injection. Having an oral version represents a significant breakthrough.
12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with Sanofi (NASD: SNY, PAR: SAN - "Sanofi "), worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme. Under the terms of the agreement, C4XD will receive an upfront payment of €7 million and could receive up to a further €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones, in addition to single digit royalties.
A new collaboration between Sano Genetics and industry partners aims to accelerate drug and biomarker discovery in ulcerative colitis (UC), a form of Inflammatory Bowel Disease (IBD).
Craig Fox, Chief Scientific Officer, C4X Discovery, added: “Identifying the right drug target for the right patient is a major but challenging goal for drug discovery, particularly for diseases with significant pathophysiological heterogeneity such as ulcerative colitis.
“Our proprietary Taxonomy3 platform will analyse the datasets produced from this research to identify novel drug targets and patient subtypes of UC which may provide a powerful insight into discovering new treatments and enrichment strategies for clinical success.”
18 December 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its annual report and accounts for the year ended 31 July 2020 has been published on the Company's website and is available to download from: www.c4xdiscovery.com.